122 related articles for article (PubMed ID: 38577760)
1. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A
Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760
[TBL] [Abstract][Full Text] [Related]
2. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [